Exploring how to improve mitochondrial function in neurodegenerative diseases
Investigating mitochondrial dysfunction in neurodegeneration using A Nanoparticle-based Synthetic Mitochondrial DNA (mtDNA) Transcription Regulator
This study is looking at ways to help people with neurodegenerative diseases by using tiny particles to deliver special treatments directly to the mitochondria, which are the energy powerhouses of our cells, to improve their function and overall health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers, the State Univ of N.j. NIH-funded |
| Lab location | 1 site (Piscataway, United States) |
| Project ID | NIH-10870203 on NIH RePORTER |
What this research studies
This research focuses on understanding mitochondrial dysfunction, which is a common issue in neurodegenerative diseases. The team aims to develop a nanoparticle-based method to effectively deliver synthetic mitochondrial DNA transcription regulators to the mitochondria, enhancing gene expression and potentially restoring normal mitochondrial function. By addressing the challenges of delivering these regulators into the mitochondria, the research seeks to create a targeted approach for treating mitochondrial-related disorders. Patients may benefit from advancements in therapies that improve mitochondrial health and function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with mitochondrial diseases or neurodegenerative disorders that involve mitochondrial dysfunction.
Not a fit: Patients with non-neurological conditions or those without mitochondrial dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve the treatment of neurodegenerative diseases linked to mitochondrial dysfunction.
How similar studies have performed: Other research has shown promise in using targeted delivery methods for mitochondrial therapies, indicating potential success for this novel approach.
Where this research is happening
Piscataway, United States
- Rutgers, the State Univ of N.j. — Piscataway, United States (Active)
Researchers
- Principal investigator: Lee, Kibum — Rutgers, the State Univ of N.j.
- Study coordinator: Lee, Kibum
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.